Gonadotropin-releasing hormone agonists: where do we stand?

被引:1
|
作者
Nawroth, Frank [1 ]
机构
[1] Amedes MVZ, Facharzt Zentrum Kinderwunsch Pranatale Med Endok, Monckebergstr 10 Barkhof, D-20095 Hamburg, Germany
来源
GYNAKOLOGISCHE ENDOKRINOLOGIE | 2019年 / 17卷 / 02期
关键词
Fertility preservation; Pregnancy rate; Sterility; female; Antineoplastic agents; Premature ovarian insufficiency; OVARIAN-FUNCTION; BREAST-CANCER; CHEMOTHERAPY; SUPPRESSION; FERTILITY; WOMEN;
D O I
10.1007/s10304-019-0240-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The article describes the current knowledge on gonadotropin-releasing hormone agonists (GnRHa) in fertility preservation. Numerous studies are now available and have formed the basis of meta-analyses in recent years. There is currently no molecular explanation for the effective action of GnRHa in the preservation of fertility. However, evidence from animal models suggests that the chemotherapeutic agent with which GnRHa is combined could be crucial to its preserving effect. According to current knowledge, the use of GnRHa significantly reduces the rate of premature ovarian failure. It may also have a positive effect on fertility. At present, there is no evidence to support the suspicion that GnRHa reduces the efficacy and safety of chemotherapy in hormone receptor-positive cancer. GnRHa' s efficacy and safety in fertility preservation need to be definitively elucidated in further investigations.
引用
收藏
页码:83 / 86
页数:4
相关论文
共 50 条
  • [21] Gonadotropin-releasing hormone agonists for ovarian protection during breast cancer chemotherapy: a systematic review and meta-analysis
    Li, Zhen-Yu
    Dong, Ying-Li
    Cao, Xiao-Zhong
    Ren, Sha-Sha
    Zhang, Zhen
    MENOPAUSE-THE JOURNAL OF THE MENOPAUSE SOCIETY, 2022, 29 (09): : 1093 - 1100
  • [22] Gonadotropin-releasing hormone analogues in chemotherapy
    Mattle, V.
    Zervomanolakis, I.
    Hadziomerovic, D.
    Mueller, J.
    von Wolff, M.
    Felberbaum, R.
    Wildt, L.
    GYNAKOLOGISCHE ENDOKRINOLOGIE, 2006, 4 (04): : 211 - 214
  • [23] Pulsatile gonadotropin-releasing hormone treatment
    Strowitzki T.
    Gynäkologische Endokrinologie, 2016, 14 (4) : 245 - 248
  • [24] Incomplete ovarian function suppression in premenopausal breast cancer patients treated with gonadotropin-releasing hormone agonists
    Lin, Jinna
    Zheng, Shuqi
    Liu, Qiang
    CANCER TREATMENT REVIEWS, 2025, 133
  • [25] Gonadotropin-releasing hormone agonists cotreatment during chemotherapy in borderline ovarian tumor and ovarian cancer patients
    Zhu Hong-lan
    Wang Yan
    Li Xiao-ping
    Wang Chao-hua
    Wang Yue
    Cui Heng
    Wang Jian-liu
    Wei Li-hui
    CHINESE MEDICAL JOURNAL, 2013, 126 (04) : 688 - 691
  • [26] Preserving fertility when choosing chemotherapy regimens - the role of gonadotropin-releasing hormone agonists
    Blumenfeld, Zeev
    Evron, Ayelet
    EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (07) : 1009 - 1020
  • [27] Gonadotropin-releasing hormone agonists during chemotherapy for ovarian function and fertility preservation for patients with early-stage breast cancer
    Abdel-Razeq, Hikmat
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 4273 - 4282
  • [28] A gonadotropin-releasing hormone agonist for the prevention of docetaxel-induced gonadal damage
    Park, Ilhae
    Lee, Sanghoon
    Ryu, Ki-Jin
    Min, Kyung-Jin
    Hong, Jin Hwa
    Song, Jae Yun
    Lee, Jae Kwan
    Lee, Nak Woo
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2017, 37 (06) : 783 - 789
  • [29] Use of gonadotropin-releasing hormone analogs in children
    Allen, Natalie G.
    Krishna, Kanthi Bangalore
    Lee, Peter A.
    CURRENT OPINION IN PEDIATRICS, 2021, 33 (04) : 442 - 448
  • [30] Gonadotropin-Releasing Hormone Antagonists Revolutionizing Gynecology
    Esencan, Ecem
    Taylor, Hugh S.
    OBSTETRICS AND GYNECOLOGY, 2022, 140 (06) : 917 - 919